What is Dendritic Cell Therapy?
Dendritic cell therapy is a type of immunotherapy that is used to treat cancer. It is also known as the Dendritic cells vaccine.
Dendritic Cell vaccine is completely customized to each person
How Is the Dendritic Cell Vaccine Made?
The most unique attribute of Dendritic cell therapy is that it is completely customized to each person and their individual cancer.
In order to create this vaccine, a blood sample is drawn from the patient. The sample is sent to the lab where it is studied and processed in order to create individualized treatments that will operate against the cancerous cells.
Some clinics such as Sanoviv perform a full autologous process, in which a biopsy sample is also taken directly from the patient’s tumor.
In these cases, when a biopsy sample is taken, at the same time, an additional blood sample is drawn as well. Both samples are then taken to a lab where they are studied and cultured in order to make a vaccine that will operate against the cells that constitute the patient’s cancer.
Each vaccine is completely unique and literally, one of a kind.
A biopsy sample is taken directly from the patient’s tumor
What is the Mechanism of Dendritic Cell Therapy?
In the lab, specialists locate specific cells in the patient’s blood that can be used to generate the vaccine.
These cells are called macrophages. A macrophage is a type of immune cell that is made in the bone marrow.
These cells are “trained” in the lab to become the strongest possible “fighter cells.” Part of this process involves testing them, changing their microenvironment, and putting them in contact with growth factors.
After all of this, the cells are then put in contact with stimuli that generate an immune response, and are bathed with an inflammatory microenvironment that activates them.
Once activated, the primed immune cells are introduced to the tumor cells in the lab.
Dendritic cells possess the ability to activate specific “memory” cells that recognize antigens in the tumor, these antigens have to be previously “presented” to them, by the dendritic cells.
With this information, dendritic cells then instruct the body to fight against certain kinds of antigens and recognize specific markers of the cancer. By doing this, they are able to turn on the body’s immune response against the patient’s exact type of cancer.
Dendritic cells turn on the body’s immune response against the patient’s exact cancer
How Does a Patient Receive the Dendritic Cell Vaccine?
The process described above takes roughly about a week. Upon its completion, the vaccine is then injected into the patient, usually as close as possible to the tumor site, near lymphatic nodes.
The patient generally receives between 4-6 vaccine shots per sample, usually on a weekly basis, though some doctors may recommend twice a week for some patients.
According to Isaac Meza, M.D., and Jose Luis Flores, Ph.D. Molecular Biomedicine, Sanoviv’s Medical Director and Head Research Scientist respectively, it is of the utmost importance for a patient to undergo integrative treatment while receiving dendritic cell therapy.
“DC therapy is best integrated with other therapies” Dr. Meza
Factors such as detoxification, a patient’s environment, nutrition and psychological state all weigh in heavily on any type of immunotherapy for cancer. It is highly recommended to integrate the vaccine as part of a full program that addresses all aspects of healing. Most clinics do not offer dendritic cell therapy on its own.
What Are the Side Effects of Dendritic Cell Therapy?
Possible side effects can include chills or a mild fever after receiving the vaccine.
The History of Dendritic Cell Therapy
Dr. William Coley is attributed with recognizing the interaction between cancer cells and the immune system in the 1890s. He went on to treat his patients with a form of a therapy called Coley’s Toxins which led to the development of Dendritic cell therapy vaccines today. The first clinical trial of dendritic cell therapy was launched in 1996 and the first dendritic cell vaccine was approved by the FDA in 2010 under the name Sipuleucel-T (Provenge).
Special thanks to Sanoviv Medical Institute, Isaac Meza, M.D., Sanoviv Medical Director, and Jose Luis Flores, Ph.D., Molecular Biomedicine, Sanoviv Head Research Scientist for their breakdown of Dendritic Cell Therapy.
